Redx Pharma (REDX) Share Price, News & Analysis

Company Overview

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers. In addition, it is developing RXC009, a potent and selective DDR1 inhibitor, which is in preclinical studies for the treatment of chronic kidney disease; Kirsten rat sarcoma virus (KRAS) inhibitor to target G12D selective and multi-KRAS profiles; RXC006/AZD5055 a porcupine inhibitor, which is in Phase 1 clinical trial for targeting fibrotic diseases, including idiopathic pulmonary fibrosis; JZP815, a pan-rapidly accelerated fibrosarcoma inhibitor that is in Phase 1 clinical trial to overcome resistance mechanisms associated with clinically approved B-RAF selective drugs; and mitogen-activated protein kinase pathway targets for oncology indications. The company has research collaboration agreements with Jazz Pharmaceuticals plc to develop JZP815, as well as discovery and preclinical development of a targeted cancer therapy on the Ras/RAF/MAP kinase pathway; and AstraZeneca plc to develop RXC006/AZD5055, a Porcupine inhibitor for the treatment of fibrotic disease. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 1.42 million shs
• Average Volume: 707,637 shs
• Market Capitalization: £58.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/19/2018
• Today: 7/17/2026

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:REDX
• CIK: N/A
• Web: redxpharma.com
• Phone: +44-151-7064747
• Fax: N/A
• Employees: 101
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£33.16 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -180.80%
• Return on Assets: -43.95%

Debt

• Debt-to-Equity Ratio: 527.00
• Current Ratio: 1.11
• Quick Ratio: 1.93

Sales & Book Value

• Annual Sales: £4.20 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 5.23
• Book Value: GBX 1 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 388,990,000
• Free Float: N/A
• Market Cap: £58.35 million
• Optionable: Not Optionable
• Beta: -0.53